SYGNIS AG

EANS-Adhoc: SYGNIS Pharma AG
SYGNIS Pharma AG announces appointment of chairman of Management Board

--------------------------------------------------------------------------------
  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
C.E.O. Interviews

17.10.2012

Ad hoc-Release according to § 15 WpHG
      
SYGNIS Pharma AG announces appointment of chairman of Management Board

Heidelberg, October 17, 2012 - SYGNIS Pharma AG (Frankfurt: LIOK; ISIN
DE000A1E9B74; Prime Standard) announces the appointment of Mrs. Pilar de la
Huerta to the Management Board of the Company and her nomination as chairman of
the Management Board (CEO) by the Supervisory Board subsequently to today's
Shareholders' Meeting.

**** end of ad hoc ****


For further information please contact:

SYGNIS Pharma AG



Peter Willinger
Co-CEO/CFO 



Tel: +49 6221 454 836



Email: {willinger@sygnis.de}[HYPERLINK: mailto:willinger@sygnis.de]





### Disclaimer
This publication is intended for information only and constitutes neither an
offer to sell nor an invitation to buy securities. Some statements included in
this press release, relating neither to proven financial results nor other
historical data, should be viewed as forward-looking, i.e. not definite. Such
statements are mainly predictions of future results, trends, plans or goals.
These statements should not be considered to be total guarantees since given
their very nature they are subject to known and unknown risks and
imponderability and can be affected by other factors as a consequence of which
the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from
the established conclusions or implied predictions contained in such statements.
SYGNIS does not undertake to publicly update or revise these statements in the
light of new information or future results or for any other reason.
###


Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


issuer:      SYGNIS Pharma AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
mail:     contact@sygnis.de
WWW:      http://www.sygnis.de
sector:      Biotechnology
ISIN:        DE000A1E9B74
indexes:     CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
             Stuttgart, regulated dealing/prime standard: Frankfurt 
language:   English
 



Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: